Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model

Haematologica. 2023 Sep 1;108(9):2513-2519. doi: 10.3324/haematol.2022.281927.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Letter

MeSH terms

  • Animals
  • Heterografts
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Mice
  • Mutation
  • Nuclear Proteins / genetics
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • fms-Like Tyrosine Kinase 3 / genetics

Substances

  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3
  • Nuclear Proteins
  • Proto-Oncogene Proteins c-bcl-2